HaemaLogiX announces issuance of USA patent for KMA.CAR-T

The provisional patent application filed in 2016 “Kappa Myeloma Antigen Chimeric Receptors and Uses Thereof” has been granted by the United States of America. The present invention provides compositions and methods for treating KMA-expressing malignancies, including chimeric antigen receptors (CARs) and T cells containing CARs (CAR-T cells). The invention also provides methods and compositions comprising CAR-T cells co-expressing other anti-tumoral agents including cytokines and antibodies.

This patent was granted in the USA on 19 April 2022 and is also under review in other jurisdictions.